Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Paxman ABFRA:B0F -0.62%81 3-1 Month Momentum % is -0.46% as of Aug. 16, 2026. GuruFocus rates FRA:B0F with a GF Score™ of 81/100 and a GF Value™ of €5.49 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 848 Medical Devices & Instruments companies, Paxman AB ranks better than 64.15% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-16), Paxman AB's 3-1 Month Momentum % is -0.46%.
The industry rank for Paxman AB's 3-1 Month Momentum % or its related term are showing as below:
FRA:B0F's 3-1 Month Momentum % is ranked better than 64.15% of 848
companies
in the Medical Devices & Instruments industry
Industry Median: -7.06
vs FRA:B0F: -0.46
Paxman AB (FRA:B0F) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Paxman AB 3-1 Month Momentum % Related Terms
FRA:B0F vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Paxman AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paxman AB 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Paxman AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Paxman AB's 3-1 Month Momentum % falls into.
Paxman AB (FRA:B0F) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paxman AB (FRA:B0F) has a 3-1 Month Momentum % of -0.46% as of Aug. 16, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Paxman AB and its competitors. According to the industry distribution chart, Paxman AB ranks #304 out of 848 companies in the Medical Devices & Instruments industry, placing it in the top 35.8%.
Is Paxman AB's 3-1 Month Momentum % too high?
Paxman AB's current 3-1 Month Momentum % is -0.46%. Based on the distribution chart, Paxman AB ranks #304 out of 848 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Paxman AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Paxman AB's 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Paxman AB ranks #304 out of 848 companies for 3-1 Month Momentum %. This puts Paxman AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Paxman AB and its competitors. Paxman AB's current 3-1 Month Momentum % is -0.46%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paxman AB stock overvalued right now?
Based on GuruFocus' analysis, Paxman AB (FRA:B0F) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.49, compared to a current price of €4.00 — trading 27.1% below its estimated fair value. The current 3-1 Month Momentum % is -0.46%. Paxman AB's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Paxman AB (FRA:B0F), the current 3-1 Month Momentum % is -0.46% as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paxman AB (FRA:B0F) Overvalued in 2026?
Based on GuruFocus' analysis, Paxman AB stock appears to be undervalued.
The current stock price of €4.00 is trading 27.1% below its estimated GF Value™ of €5.49.
GuruFocus considers Paxman AB to be Modestly Undervalued.
Key valuation signals for FRA:B0F:
3-1 Month Momentum %: -0.46%
GF Value™: €5.49 vs. price of €4.00 (27.1% below fair value)
No single metric tells the full story. See the FRA:B0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paxman AB is a Sweden-based company engaged in the development of the PAXMAN Scalp Cooling System, which has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The portfolio includes both the Paxman and Digni Capsystems with several installations in hospitals, clinics, and treatment centres world-wide.
81GF Score
Get the complete analysis for FRA:B0F
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:B0F has been successfully added to your 
